QurAlis Corporation, a biotech company focused on developing precision therapeutics for amyotrophic lateral sclerosis (ALS) and other neurological diseases, raised a seed extension that brings the total funding to date to $5.5 million. BioInnovation Capital and Viva Biotech Limited join existing biotech investors MP Healthcare Venture Management (MPH), and Amgen Ventures. Jeffrey Moore, D.Phil., M.B.A., president of MPH and Johannes Fruehauf, M.D., Ph.D., general partner at BioInnovation Capital are also joining QurAlis’ board of directors.
In addition, QurAlis won a Pfizer-sponsored Golden Ticket, and is now a resident company of Johnson & Johnson Innovation, known as JLABS. The funding and additional support will allow QurAlis to advance its preclinical research in ALS and frontotemporal dementia.